Top Page
CSPC Pharmaceutical Group
(OTC:1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 31.31B | 30.87B | 34.60B | 31.59B | 33.59B | 28.03B | Gross Profit |
| 22.35B | 21.60B | 24.40B | 22.73B | 25.47B | 21.00B | EBIT |
| 7.14B | 5.71B | 7.68B | 6.93B | 7.53B | 6.11B | EBITDA |
| 8.26B | 6.69B | 8.53B | 7.60B | 9.28B | 8.09B | Net Income Common Stockholders |
| 5.86B | 4.61B | 5.87B | 5.35B | 5.61B | 5.16B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.90B | 8.60B | 13.09B | 13.68B | 13.12B | 10.47B | Total Assets |
| 13.22B | 47.23B | 46.28B | 41.18B | 42.50B | 35.65B | Total Debt |
| 1.02B | 507.33M | 706.90M | 574.32M | 115.04M | 375.51M | Net Debt |
| -1.88B | -6.27B | -11.31B | -9.58B | -11.24B | -8.27B | Total Liabilities |
| 4.09B | 11.20B | 11.26B | 9.72B | 9.37B | 7.96B | Stockholders Equity |
| 9.05B | 32.26B | 30.07B | 29.77B | 31.79B | 26.48B |
| Cash Flow | Free Cash Flow | ||||
| 2.73B | 0.00 | 2.29B | 5.32B | 3.74B | 5.91B | Operating Cash Flow |
| 4.27B | 0.00 | 4.18B | 8.10B | 5.86B | 7.67B | Investing Cash Flow |
| -2.37B | 0.00 | 607.27M | -7.19B | -1.06B | -2.60B | Financing Cash Flow |
| -3.54B | 0.00 | -2.30B | -1.95B | -2.65B | -1.65B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $90.04B | 19.58 | 13.20% | 4.42% | -9.60% | -27.18% | |
75 Outperform | $25.66B | 14.46 | 10.17% | 3.99% | -8.91% | -34.40% | |
74 Outperform | $33.20B | 11.77 | 14.56% | 4.98% | -5.37% | 6.28% | |
72 Outperform | $968.45B | 6.59 | 6.11% | 11.71% | 37.04% | ||
66 Neutral | $82.63B | 42.70 | 6.14% | 1.39% | 7.63% | -24.23% | |
62 Neutral | HK$33.17B | 9.06 | 3.02% | ― | ― | ||
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% |
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Group Limited has announced that its drug JMT202, a recombinant fully human anti-βKlotho monoclonal antibody, has received approval from the U.S. FDA to conduct clinical trials in the United States. This development marks a significant step for the company as the drug, which targets metabolism-related diseases, has already shown promising results in preclinical studies, potentially enhancing CSPC’s market position in the treatment of hypertriglyceridemia and related conditions.
CSPC Pharmaceutical Group announced that its pivotal Phase II/III clinical study of KN026, a recombinant humanised anti-HER2 bispecific antibody, met the primary endpoint of progression-free survival with statistical significance. This development, particularly for patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, highlights KN026’s potential to improve treatment outcomes and reinforces CSPC’s position in the oncology drug market.
CSPC Pharmaceutical Group Limited has announced its upcoming annual general meeting scheduled for May 30, 2025, where key agenda items include the approval of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for a share buyback program, allowing the directors to repurchase up to 10% of the company’s issued shares, which could impact shareholder value and market perception.
CSPC Pharmaceutical Group Limited announced that its independently developed drug, SYH2068 Injection, has received approval from China’s National Medical Products Administration to conduct clinical trials. This siRNA drug targets lipoprotein(a) to treat hyperlipoproteinemia and potentially prevent atherosclerotic cardiovascular disease. Preclinical studies have shown the drug’s superior pharmacological activity and long-lasting effects, indicating promising clinical development value.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, has released its unaudited financial results for the first quarter of 2025, showing a decrease in revenue and net profit compared to the previous year. Despite the decline in financial performance, the company managed to improve its net cash flow from operating activities significantly, indicating potential operational adjustments or efficiencies.
CSPC Pharmaceutical Group has announced that its subsidiary, Shanghai JMT-BIO Technology Co., Ltd., has received approval from the U.S. FDA to conduct clinical trials for its antibody drug JMT203 in the United States. This drug targets cancer cachexia, a condition with no current GDF15 or GFRAL-targeted treatments available globally. The approval marks a significant step in CSPC’s efforts to provide an effective treatment for cancer cachexia, potentially improving the quality of life for tumor patients and enhancing the company’s position in the pharmaceutical industry.
CSPC Pharmaceutical Group has announced that its Prusogliptin and Metformin Extended-Release Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This product is the first fixed-dose combination of prusogliptin and metformin hydrochloride approved for such trials, aimed at treating adult patients with type 2 diabetes mellitus who have inadequate control with metformin alone. The approval marks a significant step in CSPC’s clinical development, offering a promising safety and tolerability profile compared to existing monotherapy options.
CSPC Pharmaceutical Group has announced that its product, Oseltamivir Phosphate for Suspension, has received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the anti-infective therapeutic area, potentially strengthening its market position and offering new treatment options for influenza A and B.
CSPC Pharmaceutical Group has announced that its investigational new drug, SYS6041, an antibody-drug conjugate, has received approval from the U.S. FDA to conduct clinical trials for advanced solid tumors in the United States. This development follows approval from China’s National Medical Products Administration and highlights the product’s promising anti-tumor effects demonstrated in preclinical studies, potentially enhancing CSPC’s position in the oncology market.
CSPC Pharmaceutical Group Limited has received approval from China’s National Medical Products Administration to conduct clinical trials for its new SYH2046 Tablets. This first-in-class small molecule drug, designed to treat heart failure following acute myocardial infarction, shows promise due to its novel mechanism of action and potential to improve cardiac function and patient outcomes compared to conventional treatments.
CSPC Pharmaceutical Group Limited announced that its new Class I bi-functional fusion protein drug, JMT108, has received approval from the U.S. FDA to conduct clinical trials in the United States. This approval, alongside prior approval in China, positions the company to advance its research on the drug’s efficacy against advanced malignant tumors, potentially enhancing its market positioning and offering promising implications for stakeholders.
CSPC Pharmaceutical Group Limited announced a final dividend of HKD 0.1 per share for the year ending December 31, 2024. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders. The dividend will be paid on July 18, 2025, following shareholder approval on May 30, 2025. This move is likely to reinforce CSPC’s market position and enhance investor confidence.
CSPC Pharmaceutical Group reported a decline in its financial performance for the year 2024, with total revenue dropping by 7.8% and profit attributable to shareholders decreasing by 26.3%. The company completed significant share buy-backs and announced further buy-back plans, reflecting strategic financial management amidst industry challenges and opportunities. The Chinese pharmaceutical industry is experiencing transformative changes driven by policy reforms and innovation incentives, which CSPC is poised to leverage for future growth.
CSPC Pharmaceutical Group has announced that its antibody-drug conjugate, SYS6040, has received approval from China’s National Medical Products Administration to commence clinical trials for advanced solid tumors. This development highlights the product’s promising anti-tumor effects and potential clinical value, with several patent applications already submitted both in China and internationally.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, released its 2024 annual financial report, showing a significant decline in revenue and net profit compared to the previous year. The report highlights a 21.98% decrease in revenue and an 87.63% drop in net profit attributable to shareholders, indicating financial challenges that may impact the company’s market positioning and stakeholder confidence.
CSPC Pharmaceutical Group Limited has announced that its board of directors will convene on March 28, 2025, to approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will determine the company’s financial performance and potential shareholder returns, impacting its market position and investor relations.
CSPC Pharmaceutical Group announced that its HER2-targeting antibody-drug conjugate, JSKN003, has received Breakthrough Therapy Designation in China for treating platinum-resistant ovarian cancer. This designation is expected to expedite the drug’s development and review process, potentially positioning it as the first anti-HER2 treatment for this condition, offering significant clinical benefits and a favorable safety profile.
CSPC Pharmaceutical Group has received approval from the U.S. FDA to conduct clinical trials for its new drug, SYH2051, a selective ATM inhibitor targeting advanced solid tumors. This approval, alongside prior approval in China, marks a significant step in the company’s oncology research, potentially enhancing its market position and offering promising treatment options for cancer patients.
CSPC Pharmaceutical Group Limited has announced that its new Class I bi-functional fusion protein drug, JMT108, has received approval from China’s National Medical Products Administration to commence clinical trials. This drug, designed to enhance anti-tumor efficacy by targeting PD-1 positive tumor infiltrating immune cells, shows promise for treating advanced malignant tumors, having demonstrated significant anti-tumor effects and a good safety profile in preclinical studies.
CSPC Pharmaceutical Group announced that its Sirolimus for Injection (albumin-bound) has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for treating malignant perivascular epithelioid cell tumor (PEComa). This designation is expected to expedite the development of the drug, potentially making it the first standard treatment for PEComa in China. The product is also undergoing clinical trials for various cancers, including breast cancer, where it addresses significant unmet needs, particularly for patients resistant to current treatments.
CSPC Pharmaceutical Group has issued a profit warning, anticipating a 26% decrease in profit for the year ending December 2024 compared to the previous year. This decline is primarily due to a 7% drop in revenue from its finished drugs business, impacted by significant price cuts in its oncology products and exclusion from a national procurement program affecting its cardiovascular drugs. The company is still finalizing its financial statements, with audited results expected in March 2025.
CSPC Pharmaceutical Group’s subsidiary, CSPC Megalith Biopharmaceutical, has entered into an exclusive license agreement with Radiance Biopharma for the development and commercialization of their anti-cancer drug SYS6005 in various international markets. This agreement allows CSPC to receive significant upfront and potential milestone payments, enhancing its position in the global pharmaceutical market and potentially advancing cancer treatment options.
CSPC Pharmaceutical Group announced that its subsidiary has obtained marketing approval from China’s National Medical Products Administration for a new indication of Enyitan, an omalizumab biosimilar. This approval marks the second indication for Enyitan in China, enhancing CSPC’s product portfolio and strengthening its position in the biosimilar market.
CSPC Pharmaceutical Group Limited announced that its novel drug, SYH2059 Tablets, has received approval from the U.S. FDA to conduct clinical trials for interstitial lung disease. This development highlights the drug’s potential effectiveness, superior efficacy, and safety profile compared to existing treatments, marking a significant advancement for patients with limited therapeutic options.
CSPC Pharmaceutical Group Limited has announced that its herpes zoster mRNA vaccine, SYS6017, has received clinical trial approval from China’s National Medical Products Administration. This vaccine, which targets the varicella-zoster virus, is designed to prevent herpes zoster infections and shows potential for a lower incidence of adverse reactions. Currently, no mRNA vaccines for VZV infections are available on the global market, placing CSPC in a potentially advantageous position to address this unmet medical need.
CSPC Pharmaceutical Group Limited has announced a change in its share registrar, effective from February 25, 2025. The new registrar will be Tricor Investor Services Limited, and this change is expected to streamline the process for the transfer of shares, potentially improving operational efficiency and service for shareholders.